Diabetic Macular Edema Market

Industry Insights-

• The Global Diabetic Macular Edema Market was valued at USD 2973.2 Million in 2021
• It is anticipated to reach USD 3414.7 Million by 2028
• A CAGR of 2.83% is anticipated over the forecast period

Market Overview-

Diabetic macular edema (DME) manifests as retinal thickening due to the accumulation of intraretinal fluid, primarily in the inner and outer plexiform layers. This is thought to be the result of hyperpermeability of the retinal vasculature. DME can occur at any level of diabetic retinopathy. The severity of diabetic retinopathy is associated with macular edema.

The pathophysiology and molecular processes involved in the development of DME are complex, requiring a better understanding of the pathogenesis and molecular pathways of the disease. In recent years, pharmaceutical companies have targeted several drug combinations to treat DME, aiming to target different pathways or different stages of the same pathway. Medications and laser surgery are two well-established treatments for preserving a patient's vision and reducing future vision loss.

Covid-19 Impact-

The Covid-19 pandemic has shown a negative impact on the growth of the global diabetic macular edema market. Outbreaks forced numerous countries to face the adverse effects of the pandemic, prompting governments to reimpose lockdown measures which has also impacted and kept on hold or postponed other health procedures such as DME treatment.

Key Players-

Some of the key players for global Diabetic Macular Edema Market are

• Bayer AG
• Allergan Plc.
• Novartis AG
• Alimera Sciences Inc
• Valeant Pharmaceuticals International Inc.
• Hoffman-La Roche Ltd.
• Pfizer
• Genentech USA Ltd.
• Sandoz Inc.
• Regeneron Pharmaceuticals Inc.
• Sirnaomics
• Iridex Corporation
• Lumenis
• Valon Lasers OY
• others

Segmentation Analysis-

By Product

• Corticosteroid Therapies  
• Anti VEGF Therapies

The global diabetic macular edema market is segmented on the product, distribution channel, product form and region & country level. Based on product, the global market is segmented into corticosteroid therapies, anti-VEGF therapies, and other off-label drugs. The anti-VEGF segment held a major market share in the global diabetic macular edema market, due to the extensive research activities by key companies and the introduction of advanced inhibitors to suppress their causative effects and prevent them from developing into a disease indication. This segment is expected to experience significant growth in the forecast period.

By Product Form

• Intravitreal Implants  
• Intravitreal Injections  

By product form, the global market is segmented into intravitreal implants and intravitreal injections. The use of anti-VEGF therapies as a major treatment option is expected to drive the adoption of intravitreal injections.

By Distribution Channel

• Hospital Pharmacies  
• Retail Pharmacies

By distribution channel, the global market is segmented into hospital pharmacies and retail pharmacies. Hospitals held a significant share of the global diabetic macular edema market. This could largely be attributed to the availability of trained professionals, advanced treatment modalities, and reimbursement for procedures in hospital settings. As a result, hospitals would dominate in terms of product distribution in the global diabetic macular edema market.

By Regional Analysis

• North America

  • U.S.
  • Canada

• Europe

  • Germany
  • France
  • U.K.
  • Italy
  • Spain
  • Sweden
  • Netherland
  • Turkey
  • Switzerland
  • Belgium
  • Rest of Europe

• Asia-Pacific

  • South Korea
  • Japan
  • China
  • India
  • Australia
  • Philippines
  • Singapore
  • Malaysia
  • Thailand
  • Indonesia
  • Rest Of APAC

• Latin America

  • Mexico
  • Colombia
  • Brazil
  • Argentina
  • Peru
  • Rest of South America

• Middle East and Africa

  • Saudi Arabia
  • UAE
  • Egypt
  • South Africa
  • Rest Of MEA

Geographically, North America is expected to dominate the global diabetic macular edema market within the forecast period due to the increasing prevalence of type 2 diabetes, rising expenditure in the healthcare sector, and the presence of a top-tier photocoagulation laser in this region. The increasing prevalence of type 2 diabetes is supplementing the growth of the market. For instance; according to the Centers for Disease Control and Prevention, on December 16th, 2021; more than 37 million Americans have diabetes (1 in 10), & approximately 90-95% of them have type 2 diabetes. Therefore, the rising prevalence of type 2 diabetes has expected to drive the market growth in this region. 

The Asia Pacific is the fastest-growing region in the global diabetic macular edema market due to increasing expenditure in the healthcare, rising cases of diabetes, and the presence of key companies in this region. For instance; according to Down to Earth, on December 6th, 2021; The estimated number of diabetic patients in the age group of 20-79 is 74.2 million in 2021 and is expected to increase to 124.8 million in 2045 in India.

Market Drivers

Increasing prevalence of diabetes among people

One of the major factors driving the growth of the diabetic macular edema market is the increasing prevalence of diabetes. The incidence of DME is higher in type 2 diabetic patients than in type 1 diabetic patients. Along with this, hyperlipidemia, fluid retention, hypertension, and increased incidence of kidney diseases are various medical diseases that increase the risk of developing DME. For instance; according to the international diabetes foundation, in 2021; 537 million adults (20-79 years) are living with diabetes one in 10. This number is projected to rise to 643 million by 2030 & 783 million by 2045. 

Rising number of research and development activities

In addition, the rising number of research and development activities is boosting the growth of the diabetic macular edema market. Along with this, increasing approval and launch of new Diabetic Macular Edema (DME) drugs will further boost the market growth rate.

For instance; on January 16th, 2020; Exonate announced a collaboration with Janssen to develop a new eye drop for the treatment of retinal vascular diseases, including wet age-related macular degeneration (AMD) and diabetic macular edema (DMO). Furthermore, increasing investment in the development of advanced technologies and an increase in the number of emerging markets will provide lucrative opportunities for the growth of the Diabetic Macular Edema (DME) market during the forecast period. For instance; on April 9th, 2022; Genentech launched a trial to study treatment for diabetic macular edema DME in underrepresented patients. 

Market Opportunities

Increasing global burden of type II diabetes to create opportunities

The World Health Organization (WHO) has estimated that the number of people with diabetes has risen from 108 million in 1980 to 422 million in 2014, which indicates a significant increase. This chronic condition is a major contributor to blindness, kidney failure, heart attacks, stroke, and lower limb amputation. Furthermore, between 2000 and 2019, the mortality rate for diabetes has increased by 3%. Type 2 diabetes is the most prevalent form of the disease and is caused by the body's inability to adequately utilize insulin. According to WHO statistics, more than 95% of all people with diabetes have type 2 diabetes.

Diabetic macular edema (DME) is a common complication of both type 1 and type 2 diabetes and is characterized by swelling of the macula, the area of the retina responsible for central vision. It is often asymptomatic in the early stages, but can progress to cause vision loss over time. The prevalence of DME varies significantly around the world, with rates as high as 45.3% in North America and as low as 11.4% in European countries. Treatment for DME often consists of anti-VEGF injections, laser therapy, and other medications.

Recent Developments-

• On March 31st, 2022; Novartis announced that the European Commission (EC) has approved Beovu (brolucizumab) 6 mg for the treatment of visual impairment due to diabetic macular edema (DME). Approval in DME represents the second indication approved by the EC for Beovu, which was first approved in 20203 for the treatment of wet age-related macular degeneration. The EC decision applies to all 27 European Union member states as well as Norway, Iceland, and Liechtenstein.
• On February 4th, 2021; The clinical trial, initiated as part of Exonate's collaboration with Janssen Pharmaceuticals, includes a dose escalation phase during which three doses of EXN 407 and a placebo were tested. This was followed by an expansion phase with a larger cohort of patient volunteers and a longer drug dosing period.

Report Analysis	Details
Historical data	2018 - 2021
Forecast Period	2022 - 2028
Market Size in 2021:	USD 2973.2 Million
Base year considered	2021
Forecast Period CAGR %:	2.83%
Market Size Expected in 2028:	USD 3414.7 Million
Tables, Charts & Figures:	175
Pages	200
Diabetic Macular Edema Companies	Bayer AG, Allergan Plc., Novartis AG , Alimera Sciences Inc, Valeant Pharmaceuticals International, Inc., Hoffman-La Roche Ltd., Pfizer, Genentech USA Ltd.,Sandoz Inc., Regeneron Pharmaceuticals Inc., Sirnaomics, Iridex Corporation, Lumenis, Valon Lasers OY, and others.
Segments Covered	By Product, By Distribution Channel, By Product Form
Regional Analysis	North America, U.S., Mexico, Canada, Europe, UK, France, Germany, Italy, Asia Pacific, China, Japan, India, Southeast Asia, South America, Brazil, Argentina, Columbia, The Middle East and Africa, GCC, Africa, Rest of the Middle East and Africa